Form 8-K - Current report:
SEC Accession No. 0001213900-25-041082
Filing Date
2025-05-08
Accepted
2025-05-08 16:18:20
Documents
15
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0241453-8k_inmune.htm   iXBRL 8-K 24917
2 PRESS RELEASE, DATED MAY 8, 2025 ea024145301ex99-1_inmune.htm EX-99.1 89745
3 GRAPHIC ex99-1_001.jpg GRAPHIC 1870
  Complete submission text file 0001213900-25-041082.txt   302990

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inmb-20250508.xsd EX-101.SCH 3017
5 XBRL LABEL FILE inmb-20250508_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE inmb-20250508_pre.xml EX-101.PRE 22360
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0241453-8k_inmune_htm.xml XML 3678
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 25926450
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)